Altimmune Inc
ALT3.625USD
+0.015+0.42%
Horário de mercado （ET）Cotações atrasadas em 15 min
282.12MValor de mercado
PerdaP/L TTM
Mais detalhes de Altimmune Inc Empresa
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
Informações da empresa
Código da empresaALT
Nome da EmpresaAltimmune Inc
Data de listagemOct 06, 2005
CEODr. Vipin K. Garg, Ph.D.
Número de funcionários59
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 06
Endereço910 Clopper Road
CidadeGAITHERSBURG
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal20878-1361
Telefone12406541450
Sitehttps://altimmune.com/
Código da empresaALT
Data de listagemOct 06, 2005
CEODr. Vipin K. Garg, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Vipin K. Garg, Ph.D.
Dr. Vipin K. Garg, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
355.08K
+5.96%
Mr. Raymond M. (Ray) Jordt
Mr. Raymond M. (Ray) Jordt
Chief Business Officer
Chief Business Officer
34.90K
+138.08%
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
26.36K
--
Mr. Gregory L. (Greg) Weaver
Mr. Gregory L. (Greg) Weaver
Chief Financial Officer
Chief Financial Officer
10.00K
--
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Independent Director
Independent Director
9.18K
--
Mr. John M. Gill
Mr. John M. Gill
Independent Director
Independent Director
2.77K
--
Dr. Catherine Angell (Cathy) Sohn, Pharm.D.
Dr. Catherine Angell (Cathy) Sohn, Pharm.D.
Independent Director
Independent Director
1.00K
--
Mr. Philip L. Hodges
Mr. Philip L. Hodges
Independent Director
Independent Director
--
--
Mr. Jerome Benedict (Jerry) Durso
Mr. Jerome Benedict (Jerry) Durso
Director
Director
--
--
Dr. M. Scot Roberts, Ph.D.
Dr. M. Scot Roberts, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Vipin K. Garg, Ph.D.
Dr. Vipin K. Garg, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
355.08K
+5.96%
Mr. Raymond M. (Ray) Jordt
Mr. Raymond M. (Ray) Jordt
Chief Business Officer
Chief Business Officer
34.90K
+138.08%
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
26.36K
--
Mr. Gregory L. (Greg) Weaver
Mr. Gregory L. (Greg) Weaver
Chief Financial Officer
Chief Financial Officer
10.00K
--
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Independent Director
Independent Director
9.18K
--
Mr. John M. Gill
Mr. John M. Gill
Independent Director
Independent Director
2.77K
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: ter, 29 de jul
Atualizado em: ter, 29 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
6.82%
The Vanguard Group, Inc.
5.42%
State Street Global Advisors (US)
4.18%
Tang Capital Management, LLC
3.39%
Geode Capital Management, L.L.C.
2.10%
Other
78.09%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
6.82%
The Vanguard Group, Inc.
5.42%
State Street Global Advisors (US)
4.18%
Tang Capital Management, LLC
3.39%
Geode Capital Management, L.L.C.
2.10%
Other
78.09%
Tipos de investidores
Investidores
Proporção
Investment Advisor
21.43%
Investment Advisor/Hedge Fund
14.99%
Hedge Fund
8.48%
Research Firm
2.10%
Individual Investor
0.76%
Bank and Trust
0.36%
Pension Fund
0.23%
Insurance Company
0.04%
Other
51.61%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
412
39.48M
48.67%
-13.27M
2025Q1
433
39.51M
48.72%
-15.43M
2024Q4
439
41.91M
54.50%
-15.25M
2024Q3
440
40.83M
57.43%
-21.59M
2024Q2
436
43.67M
61.47%
-20.29M
2024Q1
418
45.76M
64.68%
-11.45M
2023Q4
387
34.44M
49.06%
-14.90M
2023Q3
368
31.34M
59.36%
-25.59M
2023Q2
362
36.16M
68.78%
-25.80M
2023Q1
371
44.34M
90.01%
-16.05M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
5.53M
6.82%
-133.00K
-2.35%
Mar 31, 2025
The Vanguard Group, Inc.
4.39M
5.42%
-24.15K
-0.55%
Mar 31, 2025
State Street Global Advisors (US)
3.39M
4.18%
-78.45K
-2.26%
Mar 31, 2025
Tang Capital Management, LLC
2.75M
3.39%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
1.71M
2.1%
+47.38K
+2.86%
Mar 31, 2025
Two Sigma Investments, LP
1.41M
1.74%
+741.11K
+110.45%
Mar 31, 2025
Columbia Threadneedle Investments (UK)
1.32M
1.63%
-3.78M
-74.03%
Mar 31, 2025
Marshall Wace LLP
1.17M
1.44%
+1.10M
+1683.26%
Mar 31, 2025
Knoll Capital Management, LLC
1.12M
1.38%
--
--
Mar 31, 2025
Millennium Management LLC
1.11M
1.37%
+765.66K
+221.52%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Roundhill GLP-1 & Weight Loss ETF
2.06%
Virtus LifeSci Biotech Clinical Trials ETF
0.49%
Invesco NASDAQ Future Gen 200 ETF
0.32%
Federated Hermes MDT Small Cap Core ETF
0.27%
Amplify Weight Loss Drug & Treatment ETF
0.22%
SPDR S&P Biotech ETF
0.1%
Fidelity Enhanced Small Cap ETF
0.07%
iShares Micro-Cap ETF
0.07%
Direxion Daily S&P Biotech Bull 3X Shares
0.06%
Invesco Nasdaq Biotechnology ETF
0.03%
Ver Mais
Roundhill GLP-1 & Weight Loss ETF
Proporção2.06%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.49%
Invesco NASDAQ Future Gen 200 ETF
Proporção0.32%
Federated Hermes MDT Small Cap Core ETF
Proporção0.27%
Amplify Weight Loss Drug & Treatment ETF
Proporção0.22%
SPDR S&P Biotech ETF
Proporção0.1%
Fidelity Enhanced Small Cap ETF
Proporção0.07%
iShares Micro-Cap ETF
Proporção0.07%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.06%
Invesco Nasdaq Biotechnology ETF
Proporção0.03%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
